Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.

Related Articles

Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.

Biol Blood Marrow Transplant. 2017 Aug 29;:

Authors: K K Ma C, Clancy L, Simms R, Burgess J, Deo S, Blyth E, Micklethwaite KP, Gottlieb DJ

Abstract
Adoptive cellular immunotherapy has been shown to be effective in the management of CMV reactivation and disease. It is unknown whether adjuvant dendritic cell vaccination will provide additional benefit in prophylaxis or treatment of CMV in HSCT patients. In this study, we administered prophylactic CMV-peptide specific T cell infusions, followed by 2 doses of intradermal CMV peptide-pulsed dendritic cell (DC) vaccine to 4 HSCT patients. There were no immediate adverse events associated with T cell infusion or DC vaccinations. 1 of 4 patients developed grade III acute gut graft versus host disease. Immune reconstitution against CMV was detected in all 4 patients. Patients receiving CMV peptide-specific T cells and DC vaccination had peak immune reconstitution at least 10 days after the second DC vaccination. In summary, combining DC vaccine with T cell infusion appears feasible, although further study is required to ascertain its safety and efficacy in augmenting the effects of infusing donor-derived CMV-specific T cells.

PMID: 28864137 [PubMed - as supplied by publisher]

http://ift.tt/2x1VXMD